Drugs & Therapy Perspectives

, Volume 19, Issue 5, pp 10–13 | Cite as

A multipronged approach needed for successful management of sickle cell anaemia

Disease Management

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ballas SK. Sickle cell anaemia: progress in pathogenesis and treatment. Drugs 2002; 62(8): 1143–72PubMedCrossRefGoogle Scholar
  2. 2.
    Nietert PJ, Silverstein MD, Abboud MR. Sickle cell anaemia: epidemiology and cost of illness. Pharmacoeconomics 2002; 20(6): 357–66PubMedCrossRefGoogle Scholar
  3. 3.
    Hebbel RP, Boogaerts MAB, Eaton JW, et al. Erythrocyte adherence to endothelium in sickle cell anaemia: a possible determinant of disease severity. N Engl J Med 1980; 302: 992–5PubMedCrossRefGoogle Scholar
  4. 4.
    Ballas SK. Sickle cell pain: progress in pain research and management. Vol II. Seattle: IASP Press, 1998Google Scholar
  5. 5.
    Gore L, Lane PA, Quinones RR, et al. Successful cord blood transplantation for sickle cell anemia from a sibling who is human leukocyte antigen-identical: implications for comprehensive care. J Pediatr Hematol Oncol 2000; 22: 437–40PubMedCrossRefGoogle Scholar
  6. 6.
    Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anemia: clinical utility of a myelosuppressive ’switching’ agent: the Multi-center Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore) 1996; 75: 300–26CrossRefGoogle Scholar
  7. 7.
    Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995; 332: 1317–22PubMedCrossRefGoogle Scholar
  8. 8.
    Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusion for the prevention of recurrent stroke in children with sickle cell disease. Blood 1999; 94: 3022–6PubMedGoogle Scholar
  9. 9.
    Rodgers GP, Dover GJ, Uyesaka N, et al. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med 1993; 328: 73–80PubMedCrossRefGoogle Scholar
  10. 10.
    Vichinsky EP, Luban NLC, Wright E, et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001; 41: 1086–92PubMedCrossRefGoogle Scholar
  11. 11.
    Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol 2001; 38 Suppl. 1: 30–6PubMedCrossRefGoogle Scholar
  12. 12.
    Powars DR. Management of cerebral vasculopathy in children with sickle cell anaemia. Br J Haematol 2000; 108: 666–78PubMedCrossRefGoogle Scholar
  13. 13.
    Claster S, Vichinsky E. Acute chest syndrome in sickle cell disease: pathophysiology and management. J Intensive Care Med 2000; 15: 59–166CrossRefGoogle Scholar
  14. 14.
    Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med 2000; 342: 1855–65PubMedCrossRefGoogle Scholar
  15. 15.
    Rucknagel DL, Kalinyak KA, Gelfand MJ. Rib infarcts and acute chest syndrome. Lancet 1991; 337: 831–3PubMedCrossRefGoogle Scholar
  16. 16.
    Atz AM, Wessel DL. Inhaled nitric oxide in sickle cell disease with acute chest syndrome. Anesthesiology 1997; 87: 988–90PubMedCrossRefGoogle Scholar
  17. 17.
    Adams-Graves P, Kedar A, Koshy M, et al. RheothRx (Poloxamer 188) injection for the acute painful episode of sickle cell disease. Blood 1997; 90: 2041–6PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Personalised recommendations